Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245943 | 0.90 | KDM4E (0.49) | TP53KDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL3008643 | 0.89 | KDM4E (0.55) | KDM4EL3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24688715 | 0.87 | KDM4E (0.57) | KDM4EL3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3014387 | 0.87 | KDM4E (0.57) | KDM4EL3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1437259 | 0.86 | CNR1 (0.41) | KDM4EL3MBTL1THRBLMNAALOX15 | |
| SCHEMBL1437230 | 0.86 | CNR1 (0.40) | POLBKDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL32662983 | 0.84 | KDM4E (0.45) | KDM4ESMN1; SMN2LMNAMAOB | |
| SCHEMBL22372297 | 0.83 | HPGD (0.48) | TP53KDM4ERECQLNPC1RAB9A | |
| SCHEMBL22534004 | 0.79 | NPC1 (0.38) | POLBKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1437208 | 0.79 | EGLN1 (0.35) | L3MBTL1GAAALDH1A1HPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-01 | — | — | US | disclosed |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-23 | — | — | US | disclosed |
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH IP EE B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-2167474-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | Valletta Health IP EE B.V. (NL) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153385-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH B.V. (NL) | 2008-12-18 | — | — | WO | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| US-6960601-B2 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | CYP51A1, MPO, NOX5 | POLB 752/4885TP53 4335/4885KDM4E 2124/4885 |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | POLB 4458/4885TP53 4746/4885KDM4E 182/4885 |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | CYP51A1, MPO, NOX5 | POLB 752/4885TP53 4335/4885KDM4E 2124/4885 |
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | UTS2R, UACA, HCAR1 | POLB 4342/4885TP53 3779/4885KDM4E 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.